tiprankstipranks
Trending News
More News >
Editas Medicine Inc (EDIT)
NASDAQ:EDIT
US Market
Advertisement

Editas Medicine (EDIT) Stock Forecast & Price Target

Compare
3,498 Followers
See the Price Targets and Ratings of:

EDIT Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
5 Buy
5 Hold
1 Sell
Based on 11 analysts giving stock ratings to
Editas
Medicine
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EDIT Stock 12 Month Forecast

Average Price Target

$4.29
▲(73.68% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $4.29 with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 73.68% change from the last price of $2.47.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","1.75":"$1.75","3.5":"$3.5","5.25":"$5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.47,2.741538461538462,3.013076923076923,3.2846153846153845,3.556153846153846,3.827692307692308,4.099230769230769,4.3707692307692305,4.642307692307693,4.913846153846153,5.185384615384615,5.456923076923077,5.728461538461538,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.47,2.6100000000000003,2.75,2.89,3.0300000000000002,3.17,3.31,3.45,3.59,3.73,3.87,4.01,4.15,{"y":4.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.47,2.510769230769231,2.5515384615384615,2.5923076923076924,2.6330769230769233,2.6738461538461538,2.7146153846153847,2.7553846153846155,2.796153846153846,2.836923076923077,2.8776923076923078,2.918461538461538,2.959230769230769,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.14,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$6.00Average Price Target$4.29Lowest Price Target$3.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on EDIT
Truist Financial
Truist Financial
Hold
Reiterated
09/03/25
Truist Financial Sticks to Their Hold Rating for Editas Medicine (EDIT)
Wells Fargo Analyst forecast on EDIT
Wells Fargo
Wells Fargo
$3$4
Hold
61.94%
Upside
Reiterated
09/03/25
Editas Medicine price target raised to $4 from $3 at Wells FargoEditas Medicine price target raised to $4 from $3 at Wells Fargo
J.P. Morgan Analyst forecast on EDIT
J.P. Morgan
J.P. Morgan
Sell
Reiterated
09/03/25
J.P. Morgan Keeps Their Sell Rating on Editas Medicine (EDIT)
JonesTrading Analyst forecast on EDIT
JonesTrading
JonesTrading
Hold
Reiterated
09/02/25
Editas Medicine (EDIT) Receives a Hold from JonesTradingWe expect new details regarding the nomination of a candidate for the HSC program later this year, but are looking forward to seeing more preclinical data from the CVD program at a later time. Given that the company is still more than Symbol EDIT Price (Sep 1, 2025) 2.57 Market Cap (MM) 231 Dividend NA Enterprise Value (MM) 74 Shares/Units Outstanding (MM) 89.92 Dividend Yield NA Free Float (MM) 89.2 Free Float % 99.2% 52-Week Range 0.91—4.12 3-Month Avg. Daily Vol. 2,454,617 Short Interest (% of Float) NA Total Assets (MM) 211 Est. FY Cash & Cash Eq.
Evercore ISI Analyst forecast on EDIT
Evercore ISI
Evercore ISI
$5$4
Buy
61.94%
Upside
Initiated
08/22/25
Analysts Are Bullish on These Healthcare Stocks: Editas Medicine (EDIT), Tilray (TLRY)
H.C. Wainwright Analyst forecast on EDIT
H.C. Wainwright
H.C. Wainwright
$3$5
Buy
102.43%
Upside
Reiterated
08/15/25
Editas Medicine price target raised to $5 from $3 at H.C. WainwrightEditas Medicine price target raised to $5 from $3 at H.C. Wainwright
Barclays Analyst forecast on EDIT
Barclays
Barclays
$3
Hold
21.46%
Upside
Reiterated
08/13/25
Barclays Sticks to Its Hold Rating for Editas Medicine (EDIT)
Robert W. Baird Analyst forecast on EDIT
Robert W. Baird
Robert W. Baird
$4$6
Buy
142.91%
Upside
Reiterated
08/13/25
Editas Medicine price target raised to $6 from $4 at BairdEditas Medicine price target raised to $6 from $4 at Baird
Clear Street Analyst forecast on EDIT
Unknown Analyst
Clear Street
Not Ranked
Clear Street
$4
Buy
61.94%
Upside
Reiterated
08/13/25
Clear Street Reaffirms Their Buy Rating on Editas Medicine (EDIT)Reiterate our Buy rating, price target $4, as we continue to view Editas as an overlooked gene editing platform
TD Cowen Analyst forecast on EDIT
TD Cowen
TD Cowen
Buy
Reiterated
08/12/25
TD Cowen Reaffirms Their Buy Rating on Editas Medicine (EDIT)1:24 AM EDITAS MEDICINE (NASDAQ: EDIT) Buy (1) ESG Target: NA REPORTS Q2; LEAD DEVELOPMENT CANDIDATE BY SEPTEMBER, HUMAN POC DATA BY YE:26 THE TD COWEN INSIGHT EDIT ended Q2:25 with cash of $178.5MM which is expected to fund operations into Q2:27E. EDIT will nominate a lead in vivo gene editing candidate for development by September and anticipates filing an IND by Mid:26 with initial human POC data by YE:26. Remain Buy. EDIT Of A Editas presented multiple preclinical datasets highlighting its in vivo editing technology at ASGCT, TIDES and EHA.
RBC Capital Analyst forecast on EDIT
RBC Capital
RBC Capital
$4
Hold
61.94%
Upside
Reiterated
08/12/25
Editas Medicine (EDIT) Receives a Hold from RBC Capital
Bank of America Securities Analyst forecast on EDIT
Bank of America Securities
Bank of America Securities
$1
Sell
-59.51%
Downside
Reiterated
05/14/25
Bank of America Securities Remains a Sell on Editas Medicine (EDIT)
Leerink Partners Analyst forecast on EDIT
Leerink Partners
Leerink Partners
$1
Hold
-59.51%
Downside
Reiterated
03/06/25
Editas Medicine: Hold Rating Maintained Amid Strategic Advancements and Financial Stability
Citi
$5
Buy
102.43%
Upside
Reiterated
03/06/25
Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position
Chardan Capital Analyst forecast on EDIT
Chardan Capital
Chardan Capital
Hold
Downgraded
12/13/24
Editas Medicine downgraded to Neutral from Buy at ChardanEditas Medicine downgraded to Neutral from Buy at Chardan
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on EDIT
Truist Financial
Truist Financial
Hold
Reiterated
09/03/25
Truist Financial Sticks to Their Hold Rating for Editas Medicine (EDIT)
Wells Fargo Analyst forecast on EDIT
Wells Fargo
Wells Fargo
$3$4
Hold
61.94%
Upside
Reiterated
09/03/25
Editas Medicine price target raised to $4 from $3 at Wells FargoEditas Medicine price target raised to $4 from $3 at Wells Fargo
J.P. Morgan Analyst forecast on EDIT
J.P. Morgan
J.P. Morgan
Sell
Reiterated
09/03/25
J.P. Morgan Keeps Their Sell Rating on Editas Medicine (EDIT)
JonesTrading Analyst forecast on EDIT
JonesTrading
JonesTrading
Hold
Reiterated
09/02/25
Editas Medicine (EDIT) Receives a Hold from JonesTradingWe expect new details regarding the nomination of a candidate for the HSC program later this year, but are looking forward to seeing more preclinical data from the CVD program at a later time. Given that the company is still more than Symbol EDIT Price (Sep 1, 2025) 2.57 Market Cap (MM) 231 Dividend NA Enterprise Value (MM) 74 Shares/Units Outstanding (MM) 89.92 Dividend Yield NA Free Float (MM) 89.2 Free Float % 99.2% 52-Week Range 0.91—4.12 3-Month Avg. Daily Vol. 2,454,617 Short Interest (% of Float) NA Total Assets (MM) 211 Est. FY Cash & Cash Eq.
Evercore ISI Analyst forecast on EDIT
Evercore ISI
Evercore ISI
$5$4
Buy
61.94%
Upside
Initiated
08/22/25
Analysts Are Bullish on These Healthcare Stocks: Editas Medicine (EDIT), Tilray (TLRY)
H.C. Wainwright Analyst forecast on EDIT
H.C. Wainwright
H.C. Wainwright
$3$5
Buy
102.43%
Upside
Reiterated
08/15/25
Editas Medicine price target raised to $5 from $3 at H.C. WainwrightEditas Medicine price target raised to $5 from $3 at H.C. Wainwright
Barclays Analyst forecast on EDIT
Barclays
Barclays
$3
Hold
21.46%
Upside
Reiterated
08/13/25
Barclays Sticks to Its Hold Rating for Editas Medicine (EDIT)
Robert W. Baird Analyst forecast on EDIT
Robert W. Baird
Robert W. Baird
$4$6
Buy
142.91%
Upside
Reiterated
08/13/25
Editas Medicine price target raised to $6 from $4 at BairdEditas Medicine price target raised to $6 from $4 at Baird
Clear Street Analyst forecast on EDIT
Unknown Analyst
Clear Street
Not Ranked
Clear Street
$4
Buy
61.94%
Upside
Reiterated
08/13/25
Clear Street Reaffirms Their Buy Rating on Editas Medicine (EDIT)Reiterate our Buy rating, price target $4, as we continue to view Editas as an overlooked gene editing platform
TD Cowen Analyst forecast on EDIT
TD Cowen
TD Cowen
Buy
Reiterated
08/12/25
TD Cowen Reaffirms Their Buy Rating on Editas Medicine (EDIT)1:24 AM EDITAS MEDICINE (NASDAQ: EDIT) Buy (1) ESG Target: NA REPORTS Q2; LEAD DEVELOPMENT CANDIDATE BY SEPTEMBER, HUMAN POC DATA BY YE:26 THE TD COWEN INSIGHT EDIT ended Q2:25 with cash of $178.5MM which is expected to fund operations into Q2:27E. EDIT will nominate a lead in vivo gene editing candidate for development by September and anticipates filing an IND by Mid:26 with initial human POC data by YE:26. Remain Buy. EDIT Of A Editas presented multiple preclinical datasets highlighting its in vivo editing technology at ASGCT, TIDES and EHA.
RBC Capital Analyst forecast on EDIT
RBC Capital
RBC Capital
$4
Hold
61.94%
Upside
Reiterated
08/12/25
Editas Medicine (EDIT) Receives a Hold from RBC Capital
Bank of America Securities Analyst forecast on EDIT
Bank of America Securities
Bank of America Securities
$1
Sell
-59.51%
Downside
Reiterated
05/14/25
Bank of America Securities Remains a Sell on Editas Medicine (EDIT)
Leerink Partners Analyst forecast on EDIT
Leerink Partners
Leerink Partners
$1
Hold
-59.51%
Downside
Reiterated
03/06/25
Editas Medicine: Hold Rating Maintained Amid Strategic Advancements and Financial Stability
Citi
$5
Buy
102.43%
Upside
Reiterated
03/06/25
Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position
Chardan Capital Analyst forecast on EDIT
Chardan Capital
Chardan Capital
Hold
Downgraded
12/13/24
Editas Medicine downgraded to Neutral from Buy at ChardanEditas Medicine downgraded to Neutral from Buy at Chardan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Editas Medicine

1 Month
xxx
Success Rate
3/6 ratings generated profit
50%
Average Return
+1.37%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +1.37% per trade.
3 Months
xxx
Success Rate
8/15 ratings generated profit
53%
Average Return
-1.35%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of -1.35% per trade.
1 Year
Phil NadeauTD Cowen
Success Rate
10/15 ratings generated profit
67%
Average Return
+18.96%
reiterated a buy rating 24 days ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +18.96% per trade.
2 Years
xxx
Success Rate
10/15 ratings generated profit
67%
Average Return
+39.52%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +39.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EDIT Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
7
5
4
2
2
Buy
2
2
2
4
3
Hold
17
12
20
18
15
Sell
5
3
2
0
0
Strong Sell
0
0
0
0
0
total
31
22
28
24
20
In the current month, EDIT has received 5 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. EDIT average Analyst price target in the past 3 months is 4.29.
Each month's total comprises the sum of three months' worth of ratings.

EDIT Financial Forecast

EDIT Earnings Forecast

Next quarter’s earnings estimate for EDIT is -$0.30 with a range of -$0.62 to -$0.04. The previous quarter’s EPS was -$0.63. EDIT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.20% of the time in the same period. In the last calendar year EDIT has Preformed in-line its overall industry.
Next quarter’s earnings estimate for EDIT is -$0.30 with a range of -$0.62 to -$0.04. The previous quarter’s EPS was -$0.63. EDIT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.20% of the time in the same period. In the last calendar year EDIT has Preformed in-line its overall industry.

EDIT Sales Forecast

Next quarter’s sales forecast for EDIT is $4.94M with a range of $500.00K to $25.00M. The previous quarter’s sales results were $3.58M. EDIT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.29% of the time in the same period. In the last calendar year EDIT has Outperformed its overall industry.
Next quarter’s sales forecast for EDIT is $4.94M with a range of $500.00K to $25.00M. The previous quarter’s sales results were $3.58M. EDIT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.29% of the time in the same period. In the last calendar year EDIT has Outperformed its overall industry.

EDIT Stock Forecast FAQ

What is EDIT’s average 12-month price target, according to analysts?
Based on analyst ratings, Editas Medicine Inc’s 12-month average price target is 4.29.
    What is EDIT’s upside potential, based on the analysts’ average price target?
    Editas Medicine Inc has 73.68% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is EDIT a Buy, Sell or Hold?
          Editas Medicine Inc has a consensus rating of Moderate Buy which is based on 5 buy ratings, 5 hold ratings and 1 sell ratings.
            What is Editas Medicine Inc’s price target?
            The average price target for Editas Medicine Inc is 4.29. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $6.00 ,the lowest forecast is $3.00. The average price target represents 73.68% Increase from the current price of $2.47.
              What do analysts say about Editas Medicine Inc?
              Editas Medicine Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of EDIT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis